Company: InflaRx N.V.
Job title: Chief Science Officer
Treatment of Critically Ill COVID-19 Patients with Vilobelimab, a First-in-Class Anti-C5a Antibody 2:00 pm
C5a/C5aR axis plays an essential role in COVID-19 pathogenesis C5a-indued neutrophil activation is a driving force in the development of severe COVID-19 Understand how Vilobelimab treatment improves survival in critically ill COVID-19 patientsRead more
day: Track B - Day 1 PM